Hol dir die App Get the App
⭐️⭐️⭐️⭐️⭐️
44 Bewertungen
Zur App
DAX 26.458,50 0,19% Dow Jones 53.715,50 -0,27% MDAX 32.496,90 0,40% Nikkei 225 68.623,30 -0,68% S&P 500 7.782,88 -0,23% STOXX Europe 50 6.545,00 -0,27% Nasdaq 100 30.026,10 -0,20% Bitcoin 63.014,34 USD 0,29% Gold 140,71 USD 0,02% EUR/USD 1,16 USD 0,33%
DAX 26.458,50 0,19% Dow Jones 53.715,50 -0,27% MDAX 32.496,90 0,40% Nikkei 225 68.623,30 -0,68% S&P 500 7.782,88 -0,23% STOXX Europe 50 6.545,00 -0,27% Nasdaq 100 30.026,10 -0,20% Bitcoin 63.014,34 USD 0,29% Gold 140,71 USD 0,02% EUR/USD 1,16 USD 0,33%
+49 (0) 172 414 333 6
Wertpapiere

Aktie GB0009223206

Smith & Nephew plc

12,80 €

  • 0,00 €
  • |
  • 0,00 %

Your browser does not support the canvas element.

  • Aug.
  • Okt.
  • Nov.
  • Jan.
  • März
  • Mai
  • Juni
  • Aug.
  • 12.30
  • 13.40
  • 14.50
  • 15.50
  • 16.60

ERTRÄGE

Vorsicht: Das Unternehmen zahlt eine Dividende von 0,39 € pro Aktie (Rendite: 2,65%), obwohl die Ausschüttungsquote 119% beträgt – das Unternehmen schüttet mehr aus, als es verdient. Dies ist typisch für reife, schrumpfende Unternehmen oder solche in finanziellen Schwierigkeiten. Die Dividende könnte stark gefährdet sein.

0,39 $

Jährliche Dividende

2,65 %

Rendite

  • 0,24 $

    März
  • 0,15 $

    Okt.

0,13 %

Dividenden-Wachstum

  • 18

  • 19

  • 20

  • 21

  • 22

  • 23

  • 24

  • 25

  • 26

  • 27

118,93 %

Ausschüttungsquote

  • A

    119 %
  • -19 %

    G

  • A

    52 %
  • 48 %

    OCF

Historische Dividenden

    • 0,00 %
    • 0,00 $
    2019
    • 1,93 %
    • 0,38 $
    2020
    • 1,86 %
    • 0,38 $
    2021
    • 2,67 %
    • 0,37 $
    2022
    • 2,82 %
    • 0,38 $
    2023
    • 2,66 %
    • 0,38 $
    2024
    • 2,45 %
    • 0,38 $
    2025
    • 1,48 %
    • 0,24 $
    2026

UNTERNEHMEN

5,9 Mrd. $

Umsatz

  • 484,9 Mio.

    NG

  • 290,3 Mio.

    F&E

  • 4,1 Mrd.

    BG

  • 5,9 Mrd.

    U

0,73 %

Umsatz-Wachstum

  • 22

  • 23

  • 24

  • 25

  • 26

484,9 Mio. $

Nettogewinn

  • 9,0 %

    ROE
  • 8,3 %

    ROS
  • 4,6 %

    ROA
  • 23,9 %

    GPM

1,1 Mrd. $

Operativer Cashflow

  • FCF

    70 %
  • 30 %

    CapEx

5,4 Mrd. $

Eigenkapital

  • EK 51 %
  • 49 % FK

17.349

Mitarbeiter

  • 337.324,6 $

    Umsatz / MA
  • 27.950,3 $

    Gewinn / MA

KGV

27,33 $

KBV

2,46 $

KCV

17,08 $

KUV

2,27 $

EV/EBITDA

12,74 $

EV/EBIT

19,92 $

EV/FCF

22,82 $

EV/Umsatz

3,04 $

EnterpriseValue

17,8 Mrd. $

Eigenkapitalrendite

8,98 %

Umsatzrendite

8,29 %

EBIT-Marge

15,25 %

EBITDA-Marge

23,85 %

Kapitalumschlag

0,56 $

Gesamtkapitalrendite

4,61 %

Eigenkapitalquote

0,51 $

Fremdkapitalquote

0,49 $

Verschuldungsgrad

0,95 $

Dyn. Verschuldungsgrad

4,59 $

Sachinvestitionsquote

-0,30 $

Anlagendeckungsgrad 1

1,11 $

Anlagendeckungsgrad 2

0,67 $

Liquidität 1. Grades

0,42 $

Liquidität 2. Grades

1,28 $

Liquidität 3. Grades

2,95 $

Dividende pro Aktie

0,66 $

Dividendenrendite

4,35 %

Ausschüttungsquote

118,93 %

Buchwert pro Aktie

6,14 $

Cashflow pro Aktie

1,27 $
Stand: 30.06.2025 TTM

Fakten

  • Sitz

    Großbritannien

  • Hauptsitz

    Watford

  • Börsengang

    21.04.2009

  • Ausstehende Aktien

    880,19 Mio.

  • Mitarbeiter

    17,35 Tsd.

  • Währung

    GBP

  • Sektor

    Gesundheitswesen

  • Industrie

    Medical - Devices

  • Börse

    OTC

  • Ticker

    SNNUF

  • Webseite

    smith-nephew.com

Aktie

Unternehmensinfos

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products...
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.